| |
FDA Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment - DRAFT GUIDANCE
|
| |
| |
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
September 2010
This guidance document is being distributed for comment purposes only.
Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf
|
|
| |
| |
|
|
|
